Monte Rosa Therapeutics, Inc. GLUE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s operating cash flow?
- Monte Rosa Therapeutics, Inc. (GLUE) reported operating cash flow of -$37.37M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s operating cash flow increased by 17.9% year-over-year, from -$45.49M to -$37.37M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s operating cash flow has grown at a -27.3% compound annual growth rate (CAGR), from -$59.36M to -$22.8M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.